BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Tsirigotis, P. [1 ]
Girkas, K. G. [1 ]
Giannopoulou, V. [1 ]
Chondropoulos, S. [1 ]
Ioannidou, E. [1 ]
Papaxoinis, G. [1 ]
Pappa, V. [1 ]
Vasilatou, D. [1 ]
Dimoula, K. [1 ]
Kapodistrias, N. [1 ]
Papageorgiou, E. [1 ]
Economopoulos, T. [1 ]
Dervenoulas, J. [1 ]
机构：
[1] ATTIKON Gen Univ Hosp, Athens, Greece
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1109
引用
收藏
页码：436 / 436
页数：1
相关论文
共 50 条
  • [41] Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
    Azarm, Taleb
    Akbari, Mojtaba
    Azarm, Arezo
    Mohager, Hamid
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2012, 17 (01): : 8 - 14
  • [42] ASSOCIATION OF BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Saltarelli, F.
    Veggia, B.
    Moscetti, A.
    Ferrari, A.
    Tatarelli, C.
    Conte, E.
    Cox, M. C.
    Spiriti, M. A. Aloe
    Porrini, R.
    Albanesi, M.
    Mendicino, F.
    Monarca, B.
    La Verde, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 543 - 543
  • [43] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
    Avet-Loiseau, Herve
    Casneuf, Tineke
    Chiu, Christopher
    Laubach, Jacob P.
    Lee, Je-Jung
    Moreau, Philippe
    Plesner, Torben
    Nahi, Hareth
    Khokhar, Nushmia Z.
    Qi, Ming
    Schecter, Jordan
    Carlton, Victoria
    Qin, Xiang
    Liu, Kevin
    Wu, Kaida
    Zhuang, Sen H.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [44] PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
    Richardson, Paul G.
    Schlossman, Robert L.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Gasparetto, Cristina
    Mukhopadhyay, Sutapa
    Ondovik, Michael S.
    Khan, Mahmudul
    Paley, Carole S.
    Lonial, Sagar
    BLOOD, 2013, 122 (14) : 2331 - 2337
  • [45] Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
    Popat, Rakesh
    Oakervee, Heather
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Harding, Stephen
    Foot, Nicola
    Hallam, Simon
    Odeh, Liz
    Joel, Simon
    Cavenagh, Jamie
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) : 887 - 894
  • [46] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [47] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
    Jesus F. San-Miguel
    Hermann Einsele
    Philippe Moreau
    Advances in Therapy, 2016, 33 : 1896 - 1920
  • [49] The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
    San-Miguel, Jesus F.
    Einsele, Hermann
    Moreau, Philippe
    ADVANCES IN THERAPY, 2016, 33 (11) : 1896 - 1920
  • [50] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
12345